Can Seroquel and Oxcarbazepine Together Increase the Risk of Myoclonus?
Yes, both quetiapine (Seroquel) and oxcarbazepine can independently cause myoclonus, and their combination may theoretically increase this risk through additive mechanisms, though no specific drug-drug interaction studies have documented this combination.
Evidence for Individual Drug-Induced Myoclonus
Quetiapine (Seroquel)
The most recent systematic review 1 provides Level A evidence that quetiapine is associated with drug-induced myoclonus. This is the highest quality evidence available, published in 2025, specifically identifying atypical antipsychotics including quetiapine as causative agents. Additionally, a 2020 case report 2 documented quetiapine-induced myoclonus that was initially misdiagnosed as myoclonic status epilepticus due to muscular artifacts on EEG.
The FDA label for Seroquel 3 does not specifically list myoclonus as a common adverse reaction in its clinical trial data, though extrapyramidal symptoms were documented in 12.9% of adolescent patients with schizophrenia versus 5.3% for placebo.
Oxcarbazepine
The same 2025 systematic review 1 provides Level A evidence that oxcarbazepine causes drug-induced myoclonus, placing it in the antiseizure medication subclass with the highest level of evidence. This is particularly notable because oxcarbazepine is an antiepileptic drug that paradoxically can induce the very symptom it's sometimes used to treat.
Pathophysiological Mechanisms
According to the systematic review 1, drug-induced myoclonus likely involves dysregulation of:
- Serotonin (relevant for quetiapine's 5-HT receptor effects)
- Dopamine (relevant for quetiapine's D2 receptor antagonism)
- GABA (relevant for both medications)
- Glutamate (relevant for oxcarbazepine's mechanism)
The combination of these two medications could theoretically create additive effects on multiple neurotransmitter systems, potentially increasing myoclonus risk beyond either drug alone.
Clinical Implications and Management
If myoclonus develops in a patient taking both medications:
Determine the temporal relationship - Which drug was started first? Did myoclonus begin after adding the second medication?
Assess severity - Is the myoclonus interfering with daily function, causing injury risk, or affecting quality of life?
Consider dose reduction of the most recently added medication or the one most likely responsible based on timing
If severe, discontinue the most likely offending agent - Drug-induced myoclonus is typically reversible with discontinuation 1
Do not confuse with seizure activity - Obtain EEG if diagnostic uncertainty exists, as muscular artifacts can mimic epileptiform activity 2
Important Caveats
- No direct interaction studies exist examining this specific combination for myoclonus risk
- The evidence is based on individual drug effects, not combination therapy
- Most drug-induced myoclonus is reversible with appropriate management 1
- Consider alternative explanations including metabolic derangements, renal dysfunction, or underlying neurological conditions
- Guidelines for post-cardiac arrest myoclonus 4 recommend levetiracetam and valproate as first-line treatments, suggesting these antiseizure medications are less likely to cause myoclonus than oxcarbazepine
Monitor patients on this combination closely for new-onset involuntary movements, particularly during dose titration or when adding the second medication.